GSK plc
GSK plc (GLAXF): 2 pipeline candidates · 3 clinical trials. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for GSK plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$101.2B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| blu-5937 | Phase 3 |
| camlipixant | Phase 1 |
Frequently asked questions
How many drug candidates are in GSK plc's pipeline?
GSK plc (GLAXF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GSK plc's lead drug candidate?
GSK plc's most advanced tracked candidate is blu-5937 (Phase 3) for Cough.
What is GSK plc's market capitalization?
GSK plc's market capitalization is approximately $101.2B.
Who is the CEO of GSK plc?
Mr. Luke Victor Miels is the chief executive officer of GSK plc (GLAXF).
Get the full picture on GSK plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.